These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

667 related articles for article (PubMed ID: 24629273)

  • 1. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
    Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
    Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
    Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
    JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis.
    Yan H; Li H; Li Q; Zhao P; Wang W; Cao B
    PLoS One; 2015; 10(8):e0135829. PubMed ID: 26285137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
    Sun L; Ma JT; Zhang SL; Zou HW; Han CB
    Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non-small-cell lung cancer: A PRISMA-compliant meta-analysis.
    Lv WW; Zhang JJ; Zhou XL; Song Z; Wei CM
    Medicine (Baltimore); 2019 Jun; 98(23):e15806. PubMed ID: 31169681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
    Sheng Z; Zhang Y
    Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials.
    Yimaer W; Abudouyimu A; Tian Y; Magaoweiya S; Bagedati D; Wen H
    Onco Targets Ther; 2016; 9():1167-73. PubMed ID: 27022276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of vascular epithelial growth factor receptor-tyrosine kinase inhibitors in the treatment of advanced breast cancer: a meta-analysis of 12 randomized controlled trials.
    Li J; Huang S; Zheng W; Ding H; Zhang Y; Huang S; Zhang Z; Chen B; Liang Z; He G; Xiao X; Li S; Xu T; Chen X
    Curr Med Res Opin; 2013 Dec; 29(12):1691-9. PubMed ID: 23981081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
    Hong C; Mei T; Wang J
    Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis: Evaluation of safety and efficacy of the epidermal growth factor receptor-tyrosine kinase inhibitor monotherapy versus platinum-based doublets chemotherapy in East Asia.
    Zhang XF; De-Sheng LV; Li M; Sun GE; Liu CH
    Indian J Cancer; 2017; 54(1):104-114. PubMed ID: 29199672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
    Qi WX; Tang LN; He AN; Yao Y; Shen Z
    Respir Med; 2013 Aug; 107(8):1280-3. PubMed ID: 23810268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy of Single-Agent Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Biologically Selected Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis of 19 Randomized Controlled Trials.
    Li G; Gao S; Sheng Z; Li B
    Chemotherapy; 2016; 61(4):179-89. PubMed ID: 26859739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis.
    Yin X; Zhao Z; Yin Y; Shen C; Chen X; Cai Z; Wang J; Chen Z; Yin Y; Zhang B
    Clin Transl Sci; 2021 May; 14(3):919-933. PubMed ID: 33382906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
    Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.
    Li BT; Barnes TA; Chan DL; Naidoo J; Lee A; Khasraw M; Marx GM; Kris MG; Clarke SJ; Drilon A; Rudin CM; Pavlakis N
    Lung Cancer; 2016 Dec; 102():21-27. PubMed ID: 27987583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Liu ZL; Zhu WR; Zhou WC; Ying HF; Zheng L; Guo YB; Chen JX; Shen XH
    J Integr Med; 2014 Jul; 12(4):346-58. PubMed ID: 25074884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK4/6 Inhibitors in Combination With Hormone Therapy for HR
    Deng Y; Ma G; Li W; Wang T; Zhao Y; Wu Q
    Clin Breast Cancer; 2018 Oct; 18(5):e943-e953. PubMed ID: 29804650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non-Small-cell Lung Cancer on Progression-free and Overall Survival.
    Jiang T; Qiao M; Zhou F; Ren S; Su C; Zhou C
    Clin Lung Cancer; 2017 Jul; 18(4):421-431.e3. PubMed ID: 28131635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of seven randomized control trials to assess the efficacy and toxicity of combining EGFR-TKI with chemotherapy for patients with advanced NSCLC who failed first-line treatment.
    Xiao BK; Yang JY; Dong JX; Ji ZS; Si HY; Wang WL; Huang RQ
    Asian Pac J Cancer Prev; 2015; 16(7):2915-21. PubMed ID: 25854383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.